15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
10
Jul
2025
5AM-Founded Renasant Bio Secures $54.5M Seed for ADPKD Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.